{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:07:01Z","timestamp":1793506021644,"version":"4.5.0"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Yunnan Key Laboratory for Basic Research on Bone and Joint Diseases","award":["BRBJD-2021-1"],"award-info":[{"award-number":["BRBJD-2021-1"]}]},{"DOI":"10.13039\/501100003996","name":"Kunming University","doi-asserted-by":"crossref","award":["XJ20220008"],"award-info":[{"award-number":["XJ20220008"]}],"id":[{"id":"10.13039\/501100003996","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Rapamycin treatment significantly increases lifespan and ameliorates several aging-related diseases in mice, making it a potential anti-aging drug. However, there are several obvious side effects of rapamycin, which may limit the broad applications of this drug. Lipid metabolism disorders such as fatty liver and hyperlipidemia are some of those unwanted side effects. Fatty liver is characterized as ectopic lipid accumulation in livers, which is usually accompanied by increased inflammation levels. Rapamycin is also a well-known anti-inflammation chemical. How rapamycin affects the inflammation level in rapamycin-induced fatty liver remains poorly understood. Here, we show that eight-day rapamycin treatment induced fatty liver and increased liver free fatty acid levels in mice, while the expression levels of inflammatory markers are even lower than those in the control mice. Mechanistically, the upstream of the pro-inflammatory pathway was activated in rapamycin-induced fatty livers, however, there is no increased NF\u03baB nuclear translocation probably because the interaction between p65 and I\u03baB\u03b1 was enhanced by rapamycin treatment. The lipolysis pathway in the liver is also suppressed by rapamycin. Liver cirrhosis is an adverse consequence of fatty liver, while prolonged rapamycin treatment did not increase liver cirrhosis markers. Our results indicate that although fatty livers are induced by rapamycin, the fatty livers are not accompanied by increased inflammation levels, implying that rapamycin-induced fatty livers might not be as harmful as other types of fatty livers, such as high-fat diet and alcohol-induced fatty livers.<\/jats:p>","DOI":"10.1371\/journal.pone.0281888","type":"journal-article","created":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T13:23:45Z","timestamp":1677849825000},"page":"e0281888","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["Rapamycin suppresses inflammation and increases the interaction between p65 and I\u03baB\u03b1 in rapamycin-induced fatty livers"],"prefix":"10.1371","volume":"18","author":[{"given":"Chenliang","family":"Ge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changguo","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiesheng","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingbo","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8302-7425","authenticated-orcid":true,"given":"An","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,3,3]]},"reference":[{"key":"pone.0281888.ref001","first-page":"5","article-title":"Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice","author":"A Bitto","year":"2016","journal-title":"Elife"},{"issue":"7253","key":"pone.0281888.ref002","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nature08221","article-title":"Rapamycin fed late in life extends lifespan in genetically heterogeneous mice","volume":"460","author":"DE Harrison","year":"2009","journal-title":"Nature"},{"issue":"10","key":"pone.0281888.ref003","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.4161\/cc.9.10.11872","article-title":"Rapamycin and quasi-programmed aging: four years later","volume":"9","author":"MV Blagosklonny","year":"2010","journal-title":"Cell Cycle"},{"issue":"11","key":"pone.0281888.ref004","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.18632\/aging.101647","article-title":"Disease or not, aging is easily treatable","volume":"10","author":"MV Blagosklonny","year":"2018","journal-title":"Aging (Albany NY)"},{"issue":"9","key":"pone.0281888.ref005","doi-asserted-by":"crossref","first-page":"742","DOI":"10.18632\/aging.100688","article-title":"Rapamycin-induced metabolic defects are reversible in both lean and obese mice","volume":"6","author":"Y Liu","year":"2014","journal-title":"Aging"},{"issue":"6","key":"pone.0281888.ref006","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.2337\/db09-1324","article-title":"Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue","volume":"59","author":"VP Houde","year":"2010","journal-title":"Diabetes"},{"issue":"4","key":"pone.0281888.ref007","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.cmet.2013.03.003","article-title":"Molecular and genetic crosstalks between mTOR and ERRalpha are key determinants of rapamycin-induced nonalcoholic fatty liver","volume":"17","author":"C Chaveroux","year":"2013","journal-title":"Cell Metab"},{"issue":"4","key":"pone.0281888.ref008","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.cmet.2009.02.006","article-title":"Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation","volume":"9","author":"A Purushotham","year":"2009","journal-title":"Cell Metab"},{"issue":"4","key":"pone.0281888.ref009","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/hep.26167","article-title":"Resistin reduces mitochondria and induces hepatic steatosis in mice by the protein kinase C\/protein kinase G\/p65\/PPAR gamma coactivator 1 alpha pathway","volume":"57","author":"L Zhou","year":"2013","journal-title":"Hepatology"},{"issue":"1","key":"pone.0281888.ref010","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/j.jss.2012.02.023","article-title":"Multifaceted effects of rapamycin on functional recovery after spinal cord injury in rats through autophagy promotion, anti-inflammation, and neuroprotection","volume":"179","author":"HC Chen","year":"2013","journal-title":"J Surg Res"},{"issue":"8","key":"pone.0281888.ref011","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/ncb3195","article-title":"MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation","volume":"17","author":"RM Laberge","year":"2015","journal-title":"Nat Cell Biol"},{"issue":"3","key":"pone.0281888.ref012","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/acel.12587","article-title":"Rapamycin inhibits the secretory phenotype of senescent cells by a Nrf2-independent mechanism","volume":"16","author":"R Wang","year":"2017","journal-title":"Aging Cell"},{"issue":"6","key":"pone.0281888.ref013","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.biocel.2012.02.017","article-title":"Roles of c-Rel signalling in inflammation and disease","volume":"44","author":"N Fullard","year":"2012","journal-title":"Int J Biochem Cell Biol"},{"issue":"10\u201312","key":"pone.0281888.ref014","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.bbagrm.2010.05.004","article-title":"Inhibiting NF-kappaB activation by small molecules as a therapeutic strategy","volume":"1799","author":"SC Gupta","year":"2010","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"pone.0281888.ref015","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jceh.2015.02.002","article-title":"The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis","volume":"5","author":"M Sharma","year":"2015","journal-title":"Journal of clinical and experimental hepatology"},{"issue":"8","key":"pone.0281888.ref016","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.2337\/db11-0231","article-title":"The metabolically benign and malignant fatty liver","volume":"60","author":"N Stefan","year":"2011","journal-title":"Diabetes"},{"issue":"9","key":"pone.0281888.ref017","doi-asserted-by":"crossref","first-page":"14735","DOI":"10.1002\/jcb.28734","article-title":"Hypoxia inducible factor-1 promotes liver fibrosis in nonalcoholic fatty liver disease by activating PTEN\/p65 signaling pathway","volume":"120","author":"J Han","year":"2019","journal-title":"J Cell Biochem"},{"issue":"1\u20132","key":"pone.0281888.ref018","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.mce.2013.06.028","article-title":"Resistin impairs SIRT1 function and induces senescence-associated phenotype in hepatocytes","volume":"377","author":"A Yu","year":"2013","journal-title":"Molecular and cellular endocrinology"},{"issue":"8","key":"pone.0281888.ref019","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41419-019-1822-8","article-title":"Fasting and rapamycin: diabetes versus benevolent glucose intolerance","volume":"10","author":"MV Blagosklonny","year":"2019","journal-title":"Cell Death Dis"},{"issue":"12","key":"pone.0281888.ref020","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.2337\/diabetes.52.12.2882","article-title":"Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects","volume":"52","author":"D Tripathy","year":"2003","journal-title":"Diabetes"},{"issue":"7329","key":"pone.0281888.ref021","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nature09663","article-title":"A role for mitochondria in NLRP3 inflammasome activation","volume":"469","author":"R Zhou","year":"2011","journal-title":"Nature"},{"issue":"10","key":"pone.0281888.ref022","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.bbalip.2017.06.007","article-title":"G0S2: A small giant controller of lipolysis and adipose-liver fatty acid flux","volume":"1862","author":"X Zhang","year":"2017","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"issue":"12","key":"pone.0281888.ref023","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.3109\/10715762.2015.1078461","article-title":"Endoplasmic reticulum stress and Oxidative stress in the pathogenesis of Non-alcoholic fatty liver disease","volume":"49","author":"NU Ashraf","year":"2015","journal-title":"Free radical research"},{"key":"pone.0281888.ref024","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.3389\/fimmu.2018.03083","article-title":"The C\/EBP Homologous Protein (CHOP) Transcription Factor Functions in Endoplasmic Reticulum Stress-Induced Apoptosis and Microbial Infection","volume":"9","author":"H Hu","year":"2018","journal-title":"Frontiers in immunology"},{"issue":"2","key":"pone.0281888.ref025","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1002\/hep.20973","article-title":"Nonalcoholic fatty liver disease: from steatosis to cirrhosis","volume":"43","author":"GC Farrell","year":"2006","journal-title":"Hepatology"},{"issue":"6","key":"pone.0281888.ref026","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1002\/hep.24598","article-title":"Protease profiling of liver fibrosis reveals the ADAM metallopeptidase with thrombospondin type 1 motif, 1 as a central activator of transforming growth factor beta","volume":"54","author":"K Bourd-Boittin","year":"2011","journal-title":"Hepatology"},{"key":"pone.0281888.ref027","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/978-3-319-48382-5_8","article-title":"What Is Lipotoxicity?","volume":"960","author":"AB Engin","year":"2017","journal-title":"Advances in experimental medicine and biology"},{"key":"pone.0281888.ref028","first-page":"1","article-title":"Rapamycin Inhibits Nf-KappaB Activation by Autophagy to Reduce Catabolism in Human Chondrocytes","author":"Y Liu","year":"2019","journal-title":"Journal of investigative surgery: the official journal of the Academy of Surgical Research"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0281888","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T13:24:51Z","timestamp":1677849891000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0281888"}},"subtitle":[],"editor":[{"given":"David M.","family":"Ojcius","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0281888","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,3]]}}}